Sound Pharmaceuticals
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4010 Stone Way N Ste 120, Seattle, Washi...Phone Number
(206) 634-2559Website
www.soundpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Sound Pharmaceuticals
Sound Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, WA, focused on developing novel therapeutics to prevent and treat various forms of hearing loss, including sensorineural hearing loss and tinnitus. With approximately 50 million Americans affected by hearing loss, the company aims to address a significant unmet medical need, as there are currently no FDA-approved drugs for inner ear disorders. Their innovative treatments include oral therapies for acute and chronic hearing loss, as well as locally delivered options for hearing restoration. Sound Pharmaceuticals is dedicated to improving the quality of life for patients suffering from hearing-related conditions.Explore more
Sound Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sound Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Sound Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Sound Pharmaceuticals
Product Launch: Get notified when Sound Pharmaceuticals launches new products
Click to see if Sound Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Sound Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Sound Pharmaceuticals has new funding data
Check out if Sound Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sound Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Sound Pharmaceuticals
Compare insights from companies similar to Sound Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sound Pharmaceuticals
<$5M
11-50
Private
$12.1M
2001
JN
Jacqueline NguyenVice President, Operations & Development
Company Profile Activity
Activity Insights
Sound Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sound Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sound Pharmaceuticals.
Sound Pharmaceuticals financials insights
Gather financial insights about Sound Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2005
Private Equity
$7.6M
2015
Debt
$4.1M
2020
Debt
$150K
2021
Debt
$280K
Sound Pharmaceuticals Tech Stack
A closer look at the technologies used by Sound Pharmaceuticals
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Sound Pharmaceuticals has received an SBA PPP loan in the amount of $280,729 from KeyBank National Association resulting in the retention of 12 jobs.
Funding
Sound Pharmaceuticals News & Media
Sound Pharma to Present at Upcoming Life Sciences Industry Conferences
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at two upcoming industry conferences this month. 5th Inner Ear Disorders Therapeutics Summit on July 15-17 BTIG Virtual Biotechnology Conference July 29-30 Dr. Jonathan Kil, Co-Founder and CEO, will provide an update on SPI-1005, a novel oral anti-inflammatory drug. SPI-1005 is the first investigational drug to achieve its co-primary endpoints, involving purSound Pharma to Present at Upcoming Life Science Investor Conferences
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at four upcoming life science and healthcare investor conferences over the next month. 24th Annual Needham Healthcare Conference on April 9-10 25th Life Sciences Innovation Northwest on April 23-24 Citibank Biotech Private Access Investor Day on April 24 Morgan Stanley Inaugural Private Company & Investor Day on May 5 Dr. Jonathan Kil, Co-Founder and CEOSound Pharma to Present SPI-1005 Preclinical and Clinical Hearing Loss and Tinnitus Data at the Defense Health Agency Hearing Center of Excellence Symposia and ARO MWM
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it will make four presentations at the upcoming Association for Research in Otolaryngology MidWinter Meeting in Orlando, FL. “The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus” at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE) committee that will provide a comprehensive overview of invesSound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of Meniere’s Disease (STOPMD-3), achieved its co-primary endpoints for efficacy involving improvements in hearing loss and speech discrimination. Meniere’s disease (MD) is an inner ear disorder that involves fluctuating hearing loss and tinnitus, and episodic vertigo and/or dizziness. There are no FDA-a
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sound Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sound Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, WA, focused on developing novel therapeutics to prevent and treat various forms of hearing loss, including sensorineural hearing loss and tinnitus. With approximately 50 million Americans affected by hearing loss, the company aims to address a significant unmet medical nee... Read More
